StockData
Alto Neuroscience, Inc. logo

Alto Neuroscience, Inc. (ANRO) bonds

ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$24.91−2.21 (-8.15%)

Close on Nov 17, 2026Market cap $977.52MP/E –Yield –

Debt

Borrowings on the balance sheet, Sep 30, 2026

Total debt
$13.48M
$4.52M due within a year
Net debt
-$305.86M
After $319.34M of cash
Implied interest rate
18.28%
FY2025 interest ÷ average debt
Interest coverage
-26.9×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2024

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Alto Neuroscience's 10-Q for the period ended Jun 30, 2026

IssueCouponAmount issuedCarrying value
Amended Loan Agreement
Convertible at $4 a share
Floating + 1.45%$75.00M$15.00M
Convertible debt
Convertible
––$2.00M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySize
Loan and Security Agreement$35.00M

See a number that looks wrong?